advertisement
Science News
from research organizations

Treatment for common vision disorder does not improve children's reading skills

Therapy for convergence insufficiency is no better at improving reading than placebo

Date:
October 23, 2019
Source:
NIH/National Eye Institute
Summary:
Results from a clinical trial show that while vision therapy can successfully treat convergence insufficiency (CI) in children, it fails to improve their reading test scores.
Share:
advertisement

FULL STORY

Results from a clinical trial funded by the National Eye Institute (NEI) show that while vision therapy can successfully treat convergence insufficiency (CI) in children, it fails to improve their reading test scores. Investigators from the Convergence Insufficiency Treatment Trial -- Attention and Reading Trial (CITT-ART) published the results online today inOptometry and Vision Science. NEI is part of the National Institutes of Health.

CI is a common childhood vision disorder in which the eyes are unable to work together when looking at nearby objects, and the condition can make tasks like reading difficult. Eye care providers who treat CI have assumed that successful vergence/accommodative therapy, often called vision therapy, would lead to better reading fluency and comprehension.

"While in-office vision therapy can improve visual function for children with CI, this trial indicates that clinicians should not suggest that it will lead to increased reading performance," said lead study author Mitchell Scheiman, O.D., Ph.D., Salus University, Elkins Park, Pennsylvania.

When reading or performing other close work, the eyes must turn inward to converge. For children with CI, the eyes have difficulty converging accurately, which can lead to blur or double vision, causing symptoms like discomfort and difficulty maintaining concentration when reading. Results from the earlier Convergence Insufficiency Treatment Trial (CITT), published in Ophthalmology in 2008, showed office-based vision therapy to be the most effective treatment for improving convergence and ameliorating symptoms, and that treatment effects were long-lasting. This new clinical trial, CITT-ART, was designed to determine whether treating symptomatic CI would improve reading skills.

The study enrolled 310 children with symptomatic CI, ages 9 to 14 years, and randomly assigned them to two groups. About two-thirds (206) received in-office vision therapy for 16 weeks, and the remainder (104) received in-office placebo therapy for 16 weeks. The in-office vision therapy was designed to improve accommodation (focusing) and vergence (eye teaming, meaning the ability of the eyes to work together), while the placebo therapy procedures were designed to have no effect on CI.

The children's reading performance and clinical signs of CI were measured when the study began and again after completing 16 weeks of therapy. Reading comprehension was assessed using the Wechsler Individual Achievement Test- Version 3 (WIAT-III). Additional assessments included word reading and pseudoword decoding (sounding out fake words), as well as oral and silent reading fluency. Clinical signs included measures of how well the eyes work together to converge on near objects. Symptoms were measured using the Convergence Insufficiency Symptom Survey.

While all children showed improved reading comprehension on the WIAT after 16 weeks, there was statistically no difference between average reading improvement for the CI treatment group (3.68 points) and placebo group (3.80 points). Nor was in-office vision therapy better than the placebo therapy on other standardized reading tests. Meanwhile, 75-80% of children in the vision therapy group had shown significant improvement and fell into the normal range for clinical signs, compared with approximately 30% in the placebo group. These results are similar to the original CITT study. However, the latest findings show no significant difference in symptoms, with 62% of children in the vision therapy group versus 58% of children in the placebo therapy group reporting significant symptom improvement. These findings suggest that clinical measures, rather than self-reported symptoms, are critical for assessing CI severity and improvement in children.

The study was supported by National Eye Institute grant U10-EY022599.

advertisement

Story Source:

Materialsprovided byNIH/National Eye Institute.注意:内容可能被编辑风格d length.


Journal References:

  1. Scheiman M, Cotter S, Kulp M, Mitchell L, Jones-Jordan L, Gallaway M, Borsting E, Hertle R, Chase C, Schulman E, Tamkins S, Hopkins K, Coulter S, Lorenzana I, Arnold E, Sinnott L, and Denton C.A Randomized Clinical Trial of Treatment for Symptomatic Convergence Insufficiency in Children (CITT-ART).Optometry and Vision Science, Oct 23, 2019
  2. Scheiman M, Cotter S, Kulp M, Mitchell L, Jones-Jordan L, Gallaway M, Borsting E, Hertle R, Chase C, Schulman E, Tamkins S, Hopkins K, Coulter S, Lorenzana I, Roberts T, Arnold E, Sinnott L, and Denton C.Treatment of Symptomatic Convergence Insufficiency in Children enrolled in the CITT-ART Randomized Clinical Trial.Optometry and Vision Science, Oct 23, 2019

Cite This Page:

NIH/National Eye Institute. "Treatment for common vision disorder does not improve children's reading skills: Therapy for convergence insufficiency is no better at improving reading than placebo." ScienceDaily. ScienceDaily, 23 October 2019. /releases/2019/10/191023083554.htm>.
NIH/National Eye Institute. (2019, October 23). Treatment for common vision disorder does not improve children's reading skills: Therapy for convergence insufficiency is no better at improving reading than placebo.ScienceDaily. Retrieved August 15, 2023 from www.koonmotors.com/releases/2019/10/191023083554.htm
NIH/National Eye Institute. "Treatment for common vision disorder does not improve children's reading skills: Therapy for convergence insufficiency is no better at improving reading than placebo." ScienceDaily. www.koonmotors.com/releases/2019/10/191023083554.htm (accessed August 15, 2023).

Explore More
from ScienceDaily

RELATED STORIES